CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 21 enrolled
Drug / intervention
Sitagliptin +1 moredrug
Likely dose
Sitagliptin 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01600703
NCT01600703Phase 3Completed
CompareCT.gov

Sitagliptin (®Januvia) Regulation of Intestinal and Hepatic Lipoprotein Particle and Hepatic Glucose Production in Humans

University Health Network, Toronto·interventional·Posted May 17, 2012·Updated Jan 23, 2017

In Brief

A Phase 3 clinical trial evaluating Sitagliptin and Placebo for Hyperlipidemia. Completed, enrolled 21 participants across 1 site.

Detailed Summary

Recent studies in both animals and humans has demonstrated that the hormone GLP-1 (glucagon like peptide 1) reduces intestinal production of lipoprotein particles. The investigators therefore hypothesise that the drug sitagliptin which prevents the breakdown of GLP-1 will reduce intestinal lipoprotein production in humans. The investigators are unable to speculate whether sitagliptin will affect hepatic lipoprotein production because of lack of of data from animal studies or in vitro data. Sitagliptin is already an approved treatment for type 2 diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperlipidemia
CountriesCanada
CollaboratorsMerck Frosst Canada Ltd.

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 17, 2012
Enrollment StartJul 1, 2012
Primary CompletionMay 1, 2013
Study CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 14.1 years ago

Interventions

Sitagliptindrug

Sitagliptin, 100mg, oral, single dose

Placebodrug

Placebo, oral, single dose